Accessibility Menu
Medigene Ag logo

Medigene Ag(FRA) MDG1

Market Cap€256.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-100%
5 Year-98%
1 Year-96%
1 Month-30%
€0.13
-27.64%
-0.05Today
Medigene Ag last closing stock price
MetricPriceDate
Last closeEUR 0.132025-05-15
Medigene Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%EUR 0.132025-05-08
1 month-29.74%EUR 0.192025-04-15
3 month-91.39%EUR 1.552025-02-14
Year to date-87.04%EUR 1.032024-12-30
1 year-95.54%EUR 2.992024-05-15
3 year-97.34%EUR 5.012022-05-16
5 year-98.49%EUR 8.862020-05-15
Since inception-100%EUR 427.372000-06-30

Medigene Ag Financials at a Glance

Market Cap

€256.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

€0.00

P/E Ratio

0.00

Dividend

€0.00

Beta (Volatility)

0.35 (Low)

Price

€0.13

Volume

189,470

Open

€0.16

Previous Close

€0.18

Daily Range

€0.08 - €0.16

52-Week Range

€0.01 - €4.16

Estimated Earnings Date

Aug 12, 2026

MDG1 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medigene Ag

Medigene AG is a biotechnology company based in Munich, Germany, focused on developing innovative T-cell therapies for cancer treatment. Currently, the company is engaged in the liquidation of its residual assets, marking a significant transition in its operational strategy.

Products and Services
  • Development of T-cell therapies targeting various cancer types
  • Research initiatives aimed at advancing immunotherapy solutions
  • Collaboration with partners to enhance therapeutic offerings
Growth Outlook
  • Recent quarterly revenue of €1.457 million indicates ongoing operational activity
  • Gross profit margin of 77.1% reflects strong product potential
  • Current ratio of 2.53 suggests solid liquidity position for future endeavors
Financial Highlights
  • Net income for Q2 2024 was -€4.081 million, showing operational challenges
  • Cash and cash equivalents totaled €14.024 million, providing a buffer for ongoing activities
  • Trailing twelve months (TTM) revenue of €4.5 million indicates stable revenue generation
Medigene AG has a rich history in the biotechnology sector, with a focus on T-cell therapies that have the potential to revolutionize cancer treatment. Despite current challenges, the company maintains a strong liquidity position, as evidenced by its cash reserves. The recent quarterly performance highlights both the potential and the hurdles faced in the biotechnology landscape. Investors may find interest in the company's innovative approach and its strategic direction during this transitional phase.
AI Generated • Aug 12, 2026

Industry

Biotechnology

Employees

86

CEO

Selwyn Ho, PhD

Headquarters

Munich, 82152, DE

MDG1 Financials

Key Financial Metrics (TTM)

Gross Margin

72.77%

Operating Margin

-267.63%

Net Income Margin

-268.10%

Return on Equity

-55.69%

Return on Capital

-67.24%

Return on Assets

-51.01%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

€256.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.89M

Volume

189.47K

Avg. Volume

4.68K

Financials (TTM)

Gross Profit

€1.12M

Operating Income

-€4.10M

EBITDA

-€4.08M

Operating Cash Flow

-€15.12M

Capital Expenditure

-€664.00K

Free Cash Flow

-€15.78M

Cash & ST Invst.

€14.02M

Total Debt

€2.55M

Medigene Ag Performance Analysis

Medigene Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31EUR 10,463,000N/A
20222022-12-31EUR 31,247,000198.6%
20232023-12-31EUR 6,034,000-80.7%
Medigene Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Medigene Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31EUR -0.77N/A
20222022-12-31EUR -0.64-16.6%
20232023-12-31EUR -1.2594.2%
Medigene Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

€1.46M

N/A

Gross Profit

€1.12M

N/A

Gross Margin

77.14%

N/A

Market Cap

€256.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€2.94K

N/A

Employees

87

N/A

Net Income

-€4.08M

N/A

EBITDA

-€4.08M

N/A

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

€14.02M

N/A

Total Debt

€2.55M

N/A

Accounts Receivable

€499.00K

N/A

Inventory

€0.00

N/A

Long Term Debt

€1.61M

N/A

Short Term Debt

€935.00K

N/A

Return on Assets

-51.01%

N/A

Return on Invested Capital

-65.81%

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IPHYFInnate Pharma S.A.
$1.65+0.00%
GNFTFGenfit S.a.
$15.75+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About MDG1

What is the current price of Medigene Ag?

Medigene Ag is trading at €0.13 per share.

What is the 52-week range for Medigene Ag?

Over the past 52 weeks, Medigene Ag has traded between €0.01 and €4.16.

How much debt does Medigene Ag have?

As of the most recent reporting period, Medigene Ag reported total debt of €2.95M.

How much cash does Medigene Ag have on hand?

Medigene Ag reported €8.67M in cash and cash equivalents in its most recent financial results.

What is Medigene Ag’s dividend yield?

Medigene Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.